Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

31%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 2
5(38.5%)
Phase 3
4(30.8%)
Phase 1
3(23.1%)
N/A
1(7.7%)
13Total
Phase 2(5)
Phase 3(4)
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07554768Phase 2Not Yet Recruiting

Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC

Role: collaborator

NCT07543783Phase 2Not Yet Recruiting

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Role: collaborator

NCT07275814Phase 3Recruiting

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

Role: lead

NCT07168200Phase 3Recruiting

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Role: lead

NCT07522151Phase 3Not Yet Recruiting

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Role: lead

NCT06610734Phase 2Recruiting

Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)

Role: collaborator

NCT07275723Phase 3Recruiting

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions

Role: lead

NCT07231211Phase 1Recruiting

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Role: lead

NCT07123376Phase 1Completed

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

Role: lead

NCT06657560Phase 1Completed

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

Role: lead

NCT06237257Phase 2Active Not Recruiting

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Role: lead

NCT06613113Not ApplicableRecruiting

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

Role: collaborator

NCT06335355Phase 2Not Yet Recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Role: lead

All 13 trials loaded